Related Experiment Videos
Sample size estimation in phase III cancer clinical trials
D Curran1, R J Sylvester, G Hoctin Boes
1Data Center, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium. dcu@eortc.be
Summary
Calculating sample size for phase III cancer clinical trials is crucial. This paper explains key principles, factors, and provides examples for comparing proportions and survival times, aiding trial design.
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Oncology Research
Background:
- Accurate sample size determination is fundamental for the statistical validity and ethical conduct of clinical trials.
- Phase III cancer trials require robust sample size calculations to detect clinically meaningful treatment effects.
Purpose of the Study:
- To elucidate the fundamental principles of sample size calculation specifically for phase III cancer clinical trials.
- To illustrate the critical factors influencing sample size determination in oncology research.
- To provide practical examples of sample size calculations for common trial designs.
Main Methods:
- The paper outlines the conceptual framework for sample size estimation.
- It demonstrates calculations for comparing proportions and survival data.
- Methods cover considerations for endpoint selection, multiple treatment arms, factorial designs, and equivalence trials.
Main Results:
- The study provides a clear exposition of sample size calculation principles.
- Illustrative examples demonstrate the application of these principles in phase III cancer trials.
- Key factors influencing sample size, such as effect size and desired power, are highlighted.
Conclusions:
- Effective sample size calculation is essential for the success of phase III cancer clinical trials.
- Understanding the influencing factors and applying appropriate methodologies ensures trial efficiency and reliability.
- This work serves as a guide for researchers designing oncology trials.